WG Critical Care, LLC announced the FDA approval of its Meropenem IV injection (NDA215212) on July 26, 2023, positioning the manufacturer to strengthen its portfolio against existing pan-bacterial competitors. This regulatory green light is expected to provide a critical alternative for treating severe infections, potentially capturing market share in the high-demand intravenous antimicrobial landscape.